Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2,2'-(5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2. Anastrazole
3. Arimidex
4. Ici D1033
5. Zd 1033
6. Zd-1033
7. Zd1033
8. Zeneca Zd 1033
1. 120511-73-1
2. Arimidex
3. Anastrazole
4. Anastrozol
5. Zd1033
6. 2,2'-(5-((1h-1,2,4-triazol-1-yl)methyl)-1,3-phenylene)bis(2-methylpropanenitrile)
7. Ici D1033
8. Zd-1033
9. Ici-d1033
10. 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
11. Alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
12. Nsc-719344
13. Nsc-759855
14. 2z07myw1az
15. Chembl1399
16. 2,2'-[5-(1h-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
17. Chebi:2704
18. Rvg-106400
19. Nsc719344
20. Ncgc00164619-01
21. Asiolex
22. Dsstox_cid_2607
23. 2-[3-(1-cyano-1-methylethyl)-5-(1h-1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
24. Dsstox_rid_76656
25. Dsstox_gsid_22607
26. Alpha1,alpha1,alpha3,alpha3-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
27. Zd 1033
28. Arimidex (tn)
29. Smr000466301
30. Cas-120511-73-1
31. Hsdb 7462
32. Ici-d 1033
33. Sr-01000759390
34. Unii-2z07myw1az
35. Ccris 9352
36. Anastrozole [usan:usp:inn:ban]
37. Anastrozole- Bio-x
38. Arimidex (astrazeneca)
39. Anastrozole [mi]
40. Anastrozole [inn]
41. Anastrozole [jan]
42. Anastrozole [hsdb]
43. Anastrozole [usan]
44. Schembl9726
45. Anastrozole [mart.]
46. Anastrozole [usp-rs]
47. Anastrozole [who-dd]
48. Zinc941
49. 1,3-benzenediacetonitrile, Alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-
50. Mls000759396
51. Mls001424217
52. Mls006011961
53. Anastrozole (jan/usp/inn)
54. Gtpl5137
55. Dtxsid9022607
56. Bdbm10015
57. Anastrozole [orange Book]
58. Anastrozole [ep Monograph]
59. Anastrozole [usp Impurity]
60. Bcpp000401
61. Hms2052m11
62. Hms2089n10
63. Hms2235m06
64. Hms3369k05
65. Hms3394m11
66. Hms3654i18
67. Hms3715b05
68. Hms3742o21
69. Hms3866k03
70. Pharmakon1600-01502278
71. Anastrozole [usp Monograph]
72. Act03222
73. Amy42020
74. Bcp02090
75. Tox21_112238
76. Tox21_303568
77. Mfcd00866298
78. Nsc759855
79. S1188
80. Stl451008
81. Akos015894980
82. Tox21_112238_1
83. Ac-4234
84. Bcp9000301
85. Ccg-101109
86. Cs-0716
87. Db01217
88. Ks-5052
89. Nc00359
90. Nsc 719344
91. Nsc 759855
92. Sb17304
93. 2,2'-[5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
94. Ncgc00164619-02
95. Ncgc00164619-04
96. Ncgc00257356-01
97. Bt164176
98. Hy-14274
99. Sw197739-4
100. 11a731
101. C08159
102. D00960
103. Ab00639929-06
104. Ab00639929-08
105. Ab00639929-09
106. Ab00639929-10
107. Ab00639929_11
108. Ab00639929_13
109. A804526
110. Q419143
111. Sr-01000759390-4
112. Sr-01000759390-5
113. Z1522566626
114. 3-amino-3-(4-diethylamino-2-hydroxy-phenyl)-propionicacid
115. 1,.alpha.,alpha.,alpha.',.alpha.'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-
116. 2,2'-[5-(1h-1,2,4-triazol-1-yl-methyl)-1,3-phenylene]-di(2-methyl Propionitrile)
117. 2,2'-[5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropiononitrile)
118. 2,2'-[5-(1h-1,2,4-triazole-1-yl-methyl)-1,3-phenylene]di(2-methyl Propionitrile)
119. 2-[3-(2-cyano-2-propyl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropiononitrile
120. 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methyl-propanenitrile
121. .alpha.,.alpha.',.alpha.'-tetramethyl-5(1h-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
122. .alpha.,.alpha.,.alpha.',.alpha.'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
123. 1,3-benzenediacetonitrile,.alpha.,.alpha.,.alpha.',.alpha.'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-
124. 2-[3-(1-cyano-1-methylethyl)-5-[(1h-1,2,4-triazol-1-yl)methyl]phenyl]-2-methylpropanenitrile
125. Alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Molecular Weight | 293.4 g/mol |
---|---|
Molecular Formula | C17H19N5 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 293.16404563 g/mol |
Monoisotopic Mass | 293.16404563 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 456 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Anastrozole |
PubMed Health | Anastrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | Anastrozole tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor. It is chemically described as 1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molecular formul |
Active Ingredient | Anastrozole |
Dosage Form | Tablet |
Route | Oral |
Strength | 1mg |
Market Status | Prescription |
Company | Santos Biotech; Teva Pharms; Fresenius Kabi Oncol; Apotex; Accord Hlthcare; Sun Pharm Inds; Natco Pharma; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Three Rivers Pharms; Mylan; Roxane |
2 of 4 | |
---|---|
Drug Name | Arimidex |
PubMed Health | Anastrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | ARIMIDEX (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor. It is chemically described as 1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molec |
Active Ingredient | Anastrozole |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 1mg |
Market Status | Prescription |
Company | Astrazeneca |
3 of 4 | |
---|---|
Drug Name | Anastrozole |
PubMed Health | Anastrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | Anastrozole tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor. It is chemically described as 1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molecular formul |
Active Ingredient | Anastrozole |
Dosage Form | Tablet |
Route | Oral |
Strength | 1mg |
Market Status | Prescription |
Company | Santos Biotech; Teva Pharms; Fresenius Kabi Oncol; Apotex; Accord Hlthcare; Sun Pharm Inds; Natco Pharma; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Three Rivers Pharms; Mylan; Roxane |
4 of 4 | |
---|---|
Drug Name | Arimidex |
PubMed Health | Anastrozole (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | ARIMIDEX (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor. It is chemically described as 1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl). Its molec |
Active Ingredient | Anastrozole |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 1mg |
Market Status | Prescription |
Company | Astrazeneca |
Antineoplastic
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 105
Anastrozole is indicated for the first-line treatment of postmenopausal woman with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. It is also indicated for treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. /Included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 151
Anastrozole is an option for the neoadjuvant treatment of hormone receptorpositive, locally advanced breast cancer in postmenopausal women. Two phase 2, randomized, double-blind clinical trials found anastrozole to be at least as effective as tamoxifen in response rates and rates of improved surgery. A phase 2, unpublished abstract reported no differences between neoadjuvant anastrozole and chemotherapy (doxorubicin and paclitaxel) in response rates, number of patients qualifying for breast-conserving surgery, and 3-year disease-free survival. An international expert panel recommends neoadjuvant endocrine therapy in postmenopausal women who would benefit from preoperative chemotherapy but are ineligible to receive it. Anastrozole was well-tolerated. /Not included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 151
Anastrozole is not recommended for use in premenopausal women. Safety and efficacy have not been established. /Included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 151
For more Therapeutic Uses (Complete) data for ANASTROZOLE (8 total), please visit the HSDB record page.
Among patients receiving adjuvant therapy, venous thromboembolic events occurred less frequently in patients receiving anastrozole than in those receiving tamoxifen (2 versus 4%); this included deep venous thrombosis (1 versus 2%). Ischemic cerebrovascular events also occurred less frequently in patients receiving anastrozole compared with those receiving tamoxifen (1 versus 2%). Ischemic cardiovascular disease was reported in 3% of such patients receiving anastrozole. Although angina pectoris was reported more frequently in patients receiving adjuvant therapy with anastrozole than in those receiving tamoxifen (about 2 versus 1%), the incidence of myocardial infarction was similar (0.8%).
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 927
Among patients receiving anastrozole as first-line therapy, thromboembolic disease was reported in 18 patients (4%), with 5 patients experiencing venous thrombosis (including pulmonary embolus, thrombophlebitis, and retinal vein thrombosis) and 13 patients experiencing coronary and/or cerebral thrombosis (including myocardial infarction, myocardial ischemia, angina pectoris, cerebrovascular accident, cerebral ischemia, and cerebral infarct). Despite its lack of estrogenic activity, there was no evidence of an increased incidence of myocardial infarction in patients receiving anastrozole compared with those receiving tamoxifen.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 927
Among patients receiving anastrozole as second-line therapy, thromboembolic disease was reported in 3%, and thrombophlebitis occurred in 2-5%.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 927
Among patients receiving adjuvant therapy, hot flushes (flashes) occurred less frequently in patients receiving anastrozole than in those receiving tamoxifen (35 versus 40%). Among patients receiving anastrozole as first-line or second-line therapy, hot flushes occurred in 26 or 13%, respectively.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 927
For more Drug Warnings (Complete) data for ANASTROZOLE (35 total), please visit the HSDB record page.
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].
Gynaecomastia, McCune-Albright syndrome, Short stature due to Growth Hormone deficiency, Testotoxicosis
Anastrozole prevents the conversion of adrenal androgens (e.g. [testosterone]) to estrogen in peripheral and tumour tissues. As the growth of many breast cancers is stimulated and/or maintained by the presence of estrogen, anastrozole helps to treat these cancers by decreasing the levels of circulating estrogens. Anastrozole has a relatively long duration of action allowing for once daily dosing - serum estradiol is reduced by approximately 70% within 24 hours of beginning therapy with 1mg once daily, and levels remain suppressed for up to 6 days following cessation of therapy. The incidence of ischemic cardiovascular events was increased during anastrozole therapy and patients with pre-existing ischemic heart disease should consider the risks and benefits of anastrozole before beginning therapy. Anastrozole has also been reported to decrease spine and hip bone mineral density (BMD), so consideration should be given to monitoring of BMD in patients receiving long-term therapy.
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Aromatase Inhibitors
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. (See all compounds classified as Aromatase Inhibitors.)
L02BG03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L02 - Endocrine therapy
L02B - Hormone antagonists and related agents
L02BG - Aromatase inhibitors
L02BG03 - Anastrozole
Absorption
Anastrozole is rapidly absorbed and Tmax is typically reached within 2 hours of dosing under fasted conditions. Coadministration with food reduces the rate but not the overall extent of absorption - mean Cmax decreased by 16% and the median Tmax was extended to 5 hours when anastrozole was administered 30 minutes after ingestion of food, though this relatively minor alteration in absorption kinetics is not expected to result in clinically significant effects.
Route of Elimination
Hepatic metabolism accounts for approximately 85% of anastrozole elimination. Approximately 10% of the administered dosage is eliminated unchanged in the urine.
Volume of Distribution
The volume of distribution of anastrozole into brain tissue in mice is 3.19 mL/g. Distribution into the CNS is limited due to the activity of P-gp efflux pumps at the blood brain barrier, of which anastrozole is a substrate.
Clearance
Anastrozole's clearance is mainly via hepatic metabolism and can therefore be altered in patients with hepatic impairment - patients with stable hepatic cirrhosis exhibit an apparent oral clearance approximately 30% lower compared with patients with normal liver function. Conversely, renal impairment has a negligible effect on total drug clearance as the renal route is a relatively minor clearance pathway for anastrozole. In volunteers with severe renal impairment, renal clearance was reduced by 50% while total clearance was only reduced by approximately 10%.
Anastrozole is well absorbed into systemic circulation following oral administration. Plasma concentrations approach steady-state at about 7 days of once-daily dosing, and steady-state concentrations are approximately 3-4 times higher than concentrations achieved after a single dose of the drug. Food does not affect the extent of oral absorption of anastrozole.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 930
Within the therapeutic plasma concentration range, anastrozole is 40% bound to plasma proteins.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 930
Steady-state minimum plasma concentrations averaged 25.7 and 30.4 ng/mL, respectively, in white and Japanese postmenopausal women receiving anastrozole 1 mg daily for 16 days; serum estradiol and estrone sulfate concentrations were similar between the groups.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 930
It is not known whether anastrozole is distributed into milk in humans.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 930
For more Absorption, Distribution and Excretion (Complete) data for ANASTROZOLE (10 total), please visit the HSDB record page.
Anastrozole is primarily metabolized in the liver via oxidation and glucuronidation to a number of inactive metabolites, including hydroxyanastrozole (both free and glucuronidated) and anastrozole glucuronide. Oxidation to hydroxyanastrozole is catalyzed predominantly by CYP3A4 (as well as CYP3A5 and CYP2C8, to a lesser extent) and the direct glucuronidation of anastrozole appears to be catalyzed mainly by UGT1A4. Anastrozole may also undergo N-dealkylation to form triazole and 3,5-Bis-(2-methylpropiononitrile)-benzoic acid. Labels for anastrozole state the main metabolite found in plasma following administration is triazole, but a recent pharmacokinetic study was unable to detect any products of N-dealkylation _in vitro_.
Anastrozole is extensively metabolized in the liver. Metabolism of anastrozole occurs via N-dealkylation, hydroxylation, and glucuronidation. Three metabolites of anastrozole have been identified in human plasma and urine: triazole, a glucuronide conjugate of anastrozole, and a glucuronide conjugate of hydroxyanastrozole. Triazole, the major circulating metabolite of anastrozole, lacks pharmacologic activity, and the aromatase inhibiting activity of anastrozole results principally from the parent drug. In addition, there are several minor metabolites of anastrozole, accounting for less than 5% of an administered dose, which have not been identified.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 929
The elimination half-life of anastrozole is approximately 50 hours.
Following oral administration of anastrozole in postmenopausal women, a mean terminal elimination half-life of approximately 50 hours has been reported.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 930
Anastrazole exerts its anti-estrogenic effects via selective and competitive inhibition of the aromatase enzyme found predominantly in the adrenal glands, liver, and fatty tissues. Many breast cancers are hormone receptor-positive, meaning their growth is stimulated and/or maintained by the presence of hormones such as estrogen or progesterone. In postmenopausal women, estrogen is primarily derived from the conversion of adrenally-produced androgens into estrogens by the aromatase enzyme - by competitively inhibiting the biosynthesis of estrogen at these enzymes, anastrozole effectively suppresses circulating estrogen levels and, subsequently, the growth of hormone receptor-positive tumours.
Anastrozole is a nonsteroidal aromatase inhibitor that interferes with estradiol production in peripheral tissues. Adrenally generated androstenedione, the chief source of circulating estrogen in postmenopausal women, is converted by aromatase to estrone, which is further converted to estradiol. Growth of many breast cancer tumors containing estrogen receptors and aromatase can be promoted by estrogen.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 151
Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 666
Because estrogen acts as a growth factor for hormone-dependent breast cancer cells, anastrozole-induced reduction of serum and tumor concentrations of estrogen inhibits tumor growth and delays disease progression. Anastrozole selectively inhibits the conversion of androgens to estrogens. In postmenopausal women, ovarian secretion of estrogen declines and conversion of adrenal androgens (mainly androstenedione and testosterone) to estrone and estradiol in peripheral tissues (adipose, muscle, and liver), catalyzed by the aromatase enzyme, is the principal source of estrogens. Anastrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P-450 unit of the enzyme; suppression of estrogen biosynthesis in all tissues reduces serum concentrations of circulating estrogens, including estrone, estradiol, and estrone sulfate. Anastrozole selectively inhibits synthesis of estrogens and does not affect synthesis of adrenal corticosteroid, aldosterone, or thyroid hormone. In animals, anastrozole has not been shown to possess direct progestogenic, androgenic, or estrogenic activity, but alterations in the circulating concentrations of progesterone, androgens, and estrogens have been observed.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 929
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-05-11
Pay. Date : 2018-04-03
DMF Number : 21901
Submission : 2008-09-27
Status : Active
Type : II
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm :
NDC Package Code : 62756-428
Start Marketing Date : 2023-02-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-25
Pay. Date : 2012-11-15
DMF Number : 25897
Submission : 2012-03-31
Status : Active
Type : II
NDC Package Code : 58623-0041
Start Marketing Date : 2019-09-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19034
Submission : 2005-12-16
Status : Active
Type : II
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2021-11-25
Registration Number : 20211125-209-J-1160
Manufacturer Name : TAPI Czech Industries sro
Manufacturer Address : Ostravská 305/29, Komárov 747 70 Opava, Czech
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-04-21
Pay. Date : 2015-08-10
DMF Number : 20338
Submission : 2007-03-09
Status : Active
Type : II
Certificate Number : CEP 2024-160 - Rev 00
Issue Date : 2024-08-30
Type : Chemical
Substance Number : 2406
Status : Valid
Registration Number : 222MF10240
Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY
Initial Date of Registration : 2010-10-13
Latest Date of Registration :
NDC Package Code : 46014-1160
Start Marketing Date : 2021-05-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2022-10-21
Registration Number : 20221021-209-J-1387
Manufacturer Name : Excella GmbH & Co. KG
Manufacturer Address : Nurnberger Strasse 12, 90537 Feucht, Germany
Available Reg Filing : CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19025
Submission : 2005-12-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19211
Submission : 2006-02-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19496
Submission : 2006-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19025
Submission : 2005-12-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19748
Submission : 2008-02-07
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-04-21
Pay. Date : 2015-08-10
DMF Number : 20338
Submission : 2007-03-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20282
Submission : 2007-02-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19687
Submission : 2006-08-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-31
Pay. Date : 2013-07-18
DMF Number : 18335
Submission : 2005-05-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19211
Submission : 2006-02-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19496
Submission : 2006-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19034
Submission : 2005-12-16
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Lead Product(s): Alisertib,Anastrozole,Letrozole
Therapeutic Area: Oncology Brand Name: MLN8237
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2024
Lead Product(s) : Alisertib,Anastrozole,Letrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Puma Starts ALISCA™-Breast1 Trial for Alisertib in HR+, HER2- Breast Cancer
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Product Name : MLN8237
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2024
Details:
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Lead Product(s): Alisertib,Anastrozole
Therapeutic Area: Oncology Brand Name: MLN8237
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2024
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Puma Biotechnology Allowed to Proceed Under IND for Alisertib in Metastatic Breast Cancer
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Product Name : MLN8237
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2024
Details:
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Lead Product(s): Alisertib,Anastrozole
Therapeutic Area: Oncology Brand Name: MLN8237
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2023
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Product Name : MLN8237
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Details:
ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Lead Product(s): Onapristone,Anastrozole
Therapeutic Area: Oncology Brand Name: ONA-XR
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2023
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Details:
Verzenio (abemaciclib) is a small molecule CDK4/CD6 inhibitor which is under phase 3 clinical development in combination with anastrozole for the treatment of post-menopausal patients with HR+/HER2-, advanced or metastatic breast cancer.
Lead Product(s): Abemaciclib,Anastrozole
Therapeutic Area: Oncology Brand Name: Verzenio
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2023
Lead Product(s) : Abemaciclib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemacicl...
Details : Verzenio (abemaciclib) is a small molecule CDK4/CD6 inhibitor which is under phase 3 clinical development in combination with anastrozole for the treatment of post-menopausal patients with HR+/HER2-, advanced or metastatic breast cancer.
Product Name : Verzenio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2023
Details:
Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.
Lead Product(s): Ribociclib,Anastrozole
Therapeutic Area: Oncology Brand Name: Kisqali
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2023
Lead Product(s) : Ribociclib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Kisqali® Phase III NATALEE Trial Meets Primary Endpoint at Interim Analysis Demonstratin...
Details : Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.
Product Name : Kisqali
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2023
Details:
CLAR-121 is combination of testosterone undecanoate (natural ligand for the androgen receptor and anastrozole delivered by a subcutaneous implant for treatment of AR-mediated inflammatory breast disease that predominantly affects women.
Lead Product(s): Testosterone Undecanoate,Anastrozole
Therapeutic Area: Immunology Brand Name: Jatenzo
Study Phase: Phase IProduct Type: Hormone
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2022
Lead Product(s) : Testosterone Undecanoate,Anastrozole
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CLAR-121 is combination of testosterone undecanoate (natural ligand for the androgen receptor and anastrozole delivered by a subcutaneous implant for treatment of AR-mediated inflammatory breast disease that predominantly affects women.
Product Name : Jatenzo
Product Type : Hormone
Upfront Cash : Inapplicable
October 05, 2022
Details:
Kisqali (ribociclib) is the only CDK4/6 inhibitor with proven overall survival benefit across all three pivotal Phase III advanced breast cancer trials and is recognized as the only CDK4/6i with overall survival benefit in first-line HR+/HER2- advanced breast cancer.
Lead Product(s): Ribociclib,Anastrozole,Goserelin Acetate
Therapeutic Area: Oncology Brand Name: Kisqali
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2022
Lead Product(s) : Ribociclib,Anastrozole,Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Kisqali® Prolonged PFS Benefit for Pre- and Perimenopausal Patients with Aggressive HR+/...
Details : Kisqali (ribociclib) is the only CDK4/6 inhibitor with proven overall survival benefit across all three pivotal Phase III advanced breast cancer trials and is recognized as the only CDK4/6i with overall survival benefit in first-line HR+/HER2- advanced b...
Product Name : Kisqali
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2022
Details:
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR (onapristone extended release) demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary.
Lead Product(s): Onapristone,Anastrozole
Therapeutic Area: Oncology Brand Name: ONA-XR
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2022
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Context Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Details : Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR (onapristone extended release) demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2022
Details:
CLAR-121 is a proprietary combination of testosterone (T) (natural ligand for the androgen receptor; AR) and anastrozole (inhibitor of T conversion to estradiol) delivered by a subcutaneous implant for treatment of AR-mediated breast disease that predominantly affects women.
Lead Product(s): Testosterone,Anastrozole
Therapeutic Area: Immunology Brand Name: CLAR-121
Study Phase: UndisclosedProduct Type: Hormone
Sponsor: Clarus Therapeutics
Deal Size: $11.2 million Upfront Cash: $0.5 million
Deal Type: Licensing Agreement May 25, 2021
Lead Product(s) : Testosterone,Anastrozole
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Clarus Therapeutics
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement
Details : CLAR-121 is a proprietary combination of testosterone (T) (natural ligand for the androgen receptor; AR) and anastrozole (inhibitor of T conversion to estradiol) delivered by a subcutaneous implant for treatment of AR-mediated breast disease that predomi...
Product Name : CLAR-121
Product Type : Hormone
Upfront Cash : $0.5 million
May 25, 2021
2,2'-(5-Methylbenzene-1,3-Diyl)Bis(2-Methylpropane...
CAS Number : 120511-72-0
End Use API : Anastrozole
About The Company : Suanfarma founded in 1993, is a B2B life science partner committed to health advancement by developing, manufacturing, & distributing high-quality APIs for the ...
CAS Number : 41253-21-8
End Use API : Anastrozole
About The Company : Dasami Lab Private Limited incorporated with MCA on 24 July 2015. The Dasami Lab Private Limited is listed in the class of pvtltd company and classified as Non ...
3,5-Bis (2-cyanoprop-2-yl )benzyl
CAS Number : 120511-84-4
End Use API : Anastrozole
About The Company : Innovassynth Technologies (I) Ltd. formerly known as Chemicals Division of Indian Organic Chemicals Ltd. came in to existence since 1st August 2002. It is a par...
3,5-Bis 2-cyano isopropyl toluene
CAS Number : 120511-72-0
End Use API : Anastrozole
About The Company : Innovassynth Technologies (I) Ltd. formerly known as Chemicals Division of Indian Organic Chemicals Ltd. came in to existence since 1st August 2002. It is a par...
3,5-Bis(2-cyanoisopropyl)toluene
CAS Number : 120511-72-0
End Use API : Anastrozole
About The Company : Integrin Life Sciences Pvt. Ltd. is one of the growing pharmaceutical API, advanced chemical intermediates manufacturing companies in India. Our Plant is Locate...
1-Methylbenzene-3,5-diacetonitrile
CAS Number : 120511-74-2
End Use API : Anastrozole
About The Company : The division was established in 1981 as a Specialty Chemicals Division with a focus to manufacture specialty chemicals and pharmaceutical intermediates. In Apri...
3,5-(2-Methylpropionitrilo) toluene
CAS Number : 120511-72-0
End Use API : Anastrozole
About The Company : The division was established in 1981 as a Specialty Chemicals Division with a focus to manufacture specialty chemicals and pharmaceutical intermediates. In Apri...
3,5-(2-Methylpropionitrilo) benzylbromide
CAS Number : 120511-84-4
End Use API : Anastrozole
About The Company : The division was established in 1981 as a Specialty Chemicals Division with a focus to manufacture specialty chemicals and pharmaceutical intermediates. In Apri...
3,5-Bis-(2-cyanoisopropyl) toluene
CAS Number : 1210-35-1
End Use API : Anastrozole
About The Company : LUNA Chemicals Co.,Ltd. markets and manufactures world-class quality Active Pharmaceutical Ingredients and intermediate chemicals for generic pharmaceutical com...
2,2'-(5-Bromomethyl-1,3-phenylene)-di(2- Methylpro...
CAS Number : 120511-84-4
End Use API : Anastrozole
About The Company : Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and Manufacturing APIs and Advanced Intermediates for Activ...
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
21
PharmaCompass offers a list of Anastrozole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Anastrozole manufacturer or Anastrozole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Anastrozole manufacturer or Anastrozole supplier.
PharmaCompass also assists you with knowing the Anastrozole API Price utilized in the formulation of products. Anastrozole API Price is not always fixed or binding as the Anastrozole Price is obtained through a variety of data sources. The Anastrozole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Anastrozole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anastrozole, including repackagers and relabelers. The FDA regulates Anastrozole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anastrozole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Anastrozole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Anastrozole supplier is an individual or a company that provides Anastrozole active pharmaceutical ingredient (API) or Anastrozole finished formulations upon request. The Anastrozole suppliers may include Anastrozole API manufacturers, exporters, distributors and traders.
click here to find a list of Anastrozole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Anastrozole DMF (Drug Master File) is a document detailing the whole manufacturing process of Anastrozole active pharmaceutical ingredient (API) in detail. Different forms of Anastrozole DMFs exist exist since differing nations have different regulations, such as Anastrozole USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Anastrozole DMF submitted to regulatory agencies in the US is known as a USDMF. Anastrozole USDMF includes data on Anastrozole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Anastrozole USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Anastrozole suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Anastrozole Drug Master File in Japan (Anastrozole JDMF) empowers Anastrozole API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Anastrozole JDMF during the approval evaluation for pharmaceutical products. At the time of Anastrozole JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Anastrozole suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Anastrozole Drug Master File in Korea (Anastrozole KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Anastrozole. The MFDS reviews the Anastrozole KDMF as part of the drug registration process and uses the information provided in the Anastrozole KDMF to evaluate the safety and efficacy of the drug.
After submitting a Anastrozole KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Anastrozole API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Anastrozole suppliers with KDMF on PharmaCompass.
A Anastrozole CEP of the European Pharmacopoeia monograph is often referred to as a Anastrozole Certificate of Suitability (COS). The purpose of a Anastrozole CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Anastrozole EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Anastrozole to their clients by showing that a Anastrozole CEP has been issued for it. The manufacturer submits a Anastrozole CEP (COS) as part of the market authorization procedure, and it takes on the role of a Anastrozole CEP holder for the record. Additionally, the data presented in the Anastrozole CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Anastrozole DMF.
A Anastrozole CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Anastrozole CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Anastrozole suppliers with CEP (COS) on PharmaCompass.
A Anastrozole written confirmation (Anastrozole WC) is an official document issued by a regulatory agency to a Anastrozole manufacturer, verifying that the manufacturing facility of a Anastrozole active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Anastrozole APIs or Anastrozole finished pharmaceutical products to another nation, regulatory agencies frequently require a Anastrozole WC (written confirmation) as part of the regulatory process.
click here to find a list of Anastrozole suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Anastrozole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Anastrozole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Anastrozole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Anastrozole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Anastrozole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Anastrozole suppliers with NDC on PharmaCompass.
Anastrozole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Anastrozole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anastrozole GMP manufacturer or Anastrozole GMP API supplier for your needs.
A Anastrozole CoA (Certificate of Analysis) is a formal document that attests to Anastrozole's compliance with Anastrozole specifications and serves as a tool for batch-level quality control.
Anastrozole CoA mostly includes findings from lab analyses of a specific batch. For each Anastrozole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Anastrozole may be tested according to a variety of international standards, such as European Pharmacopoeia (Anastrozole EP), Anastrozole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anastrozole USP).